Abstract
Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing.
Keywords: Coronary artery disease, hyperlipidemia, hypertension, pharmacogenetics, pharmacogenomics.
Current Molecular Medicine
Title:Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Volume: 14 Issue: 7
Author(s): P. Vanichakarn, J. Hwa and J. Stitham
Affiliation:
Keywords: Coronary artery disease, hyperlipidemia, hypertension, pharmacogenetics, pharmacogenomics.
Abstract: Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing.
Export Options
About this article
Cite this article as:
Vanichakarn P., Hwa J. and Stitham J., Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811115517
DOI https://dx.doi.org/10.2174/1566524014666140811115517 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is There a Role for Oral Anticoagulant Therapy in Patients with Peripheral Arterial Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders A Case Report of Necrotizing Fasciitis after Cesarean Delivery
Current Women`s Health Reviews Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research Determination of Lipoic Acid in the form of 2-S-pyridinium Derivative by High-performance Liquid Chromatography with Ultraviolet Detection
Current Analytical Chemistry The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design In-vitro Studies on α-Amylase, α-Glucosidase and Aldose Reductase Inhibitors found in Endophytic Fungi Isolated from Ocimum sanctum
Current Enzyme Inhibition Endothelial Dysfunction, Oxidative Stress and Inflammation in Atherosclerosis: Beneficial Effects of Statins
Current Medicinal Chemistry Synthesis and Antihypertensive Activity of Novel Quinazolin-4(3H)-one Derivatives
Central Nervous System Agents in Medicinal Chemistry Biomarkers of Lung Tissue Remodeling in Pulmonary Diseases: Implications for Clinical Practice and Research
Current Respiratory Medicine Reviews Immunotherapy in a Rabbit Model of Alzheimer’s Disease
Drug Delivery Letters Heme Oxygenase in Regulation of Renal Function and Blood Pressure
Current Hypertension Reviews New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Non-peptide Antagonists and Agonists of the Bradykinin B2 Receptor
Current Medicinal Chemistry Renal Ischemia: How Commonly Does it Cause Renal Failure?
Current Hypertension Reviews Adverse HBOC-Endothelial Dysfunction Synergism: A Possible Contributor to Adverse Clinical Outcomes?
Current Drug Discovery Technologies Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Editorial (Hot Topic: Flavoproteins and Flavoenzymes with Biomedical and Therapeutic Impact)
Current Pharmaceutical Design Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry Granulocyte Colony-stimulating Factor and Bone Marrow Mononuclear Cells for Stroke Treatment in the Aged Brain
Current Neurovascular Research Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets